Human KRAS (2-185, G12C) Protein, His Tag (active enzyme)
分子別名(Synonym)
GTPase Kras,K-Ras 2,Ki-Ras,c-K-ras,c-Ki-ras,KRAS2,RASK2,C-K-RAS,CFC2,K-RAS2A,K-RAS2B,K-RAS4A,K-RAS4B,KI-RAS,KRAS1,KRAS2,NS,NS3,RASK2,KRAS
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human KRAS (2-185, G12C) Protein, His Tag (KRS-H51H3) is expressed from E. coli cells. It contains AA Thr 2 - Cys 185 (Accession # P01116-2 (G12C)).
Predicted N-terminus: Met
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 23.0 kDa. The protein migrates as 23-25 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 20 mM Tris, 500 mM NaCl, pH 7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
KRAS(Kirsten大鼠肉瘤2病毒癌基因同源物)基因是一種原癌基因,編碼一種名為KRAS的小GTP酶轉(zhuǎn)導(dǎo)蛋白。KRAS也被稱為Ki-Ras、c-K-Ras和c-Ki-ras。Ras蛋白結(jié)合GDP/GTP并具有內(nèi)在的GTP酶活性。在調(diào)節(jié)細(xì)胞增殖中發(fā)揮重要作用,通過以ZNF304依賴的方式誘導(dǎo)癌癥(CRC)細(xì)胞中腫瘤抑制基因(TSG)的轉(zhuǎn)錄沉默來促進(jìn)致癌事件。RAS是人類癌癥中最常見的突變癌基因之一,但RAS基因突變的頻率和分布并不均勻。具體來說,甘氨酸12(G12)的突變通過干擾GAP結(jié)合和GAP刺激的GTP水解來引起RAS激活。參考文獻(xiàn)表明,該途徑可能成為潛在的治療靶點。
關(guān)鍵字: KRAS;KRAS蛋白;KRAS重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。